CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neonc Technologies Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neonc Technologies Holdings Inc
2 Dole Drive
Phone: (310) 663-7831p:310 663-7831 WESTLAKE VILLAGE, CA  91362  United States
Business Summary
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, including aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. It is developing drug delivery methods to be used in combination with drug candidates. It has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH), which is administered to brain cancer patients via intranasal delivery. Its second lead product, NEO212, is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol, has completed preclinical testing and has received investigational new drug (IND) approval from the United States Food and Drug Administration (FDA).
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Secretary Amir F.Heshmatpour 56 1/1/2023 1/1/2023
Chairman of the Board, Chief Executive Officer Thomas C.Chen 59 5/1/2023 4/1/2023
Chief Financial Officer, Director KeithlyGarnett 49 4/1/2023 1/1/2023
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 3 (As of 9/30/2023)
Outstanding Shares: 20,357,470 (As of 9/30/2023)
Federal Tax Id: 921954864


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024